A Clinical comparison between Varunadi tablet and Eladi tablet to control blood calcium level and in the treatment of urinary stone

A Clinico-comparative study of Varunadi Ghanvati and Eladi Ghanvati in the Modulation of Serum calcium level and management of Mutrashmari w.s.r. Urinary calculus - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/014168

Enrollment

Registered

2018-05-29

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N22- Calculus of urinary tract in diseases classified elsewhere Health Condition 2: null- Patients with known case of uolithiasis diagnosed by USG and other clinical methods will be included in the study conclusive of exclusion criteria. Health Condition 3: N20-N23- Urolithiasis

Interventions

Intervention1: Eladi Ghanvati: Eladi Ghanvati will be prepared from the Decoction of Eladi Drugs, Which are mentioned in the Chakradatta Ashmari adhikaar Chapter 29 Dose : 2 tab ( Each of 500mg) Frequ

Eligibility

Inclusion criteria

Inclusion criteria: 1.Pain in the both, renal angle and loin region, radiating (referring) towards groin. 2.Burning micturition with or without pain. 3.Crystaluria. 4.Patients with age in between 18 to 80 years irrespective of gender, caste, religion and region, etc. 5.Stone size upto 10 mm evident in USG

Exclusion criteria

Exclusion criteria: Patients of urolithiasis having disease or/and under any medication that affects study,study drug and its result or prognosis will be excluded. 1. Case of Medical emergency or immediate surgical intervention. 2. Cases with severe hydronephrosis. 3. Severe Hematuria. 4. Acute or chronic renal disease. 5. Acute retention of urine for more than 24 hours.

Design outcomes

Primary

Measure	Time frame
Notify improvement in classical as well as presented signs and symptoms, imagining methods and laboratory investigations in the patients of both groups will be assessed as individual and comparative aspectsTimepoint: After 60 days of trial	—

Secondary

Measure	Time frame
Not ApplicableTimepoint: Not Applicable	—

Countries

India

Contacts

Public ContactDr Alankruta R Dave

Institute of Postgraduate Teaching & Research in Ayurveda

alankruta@yahoo.com9824171817

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026